JAK Inhibitors Start To Come Of Age In Rheumatoid Arthritis
Oral class has gotten off to slow start, but data for range of JAK inhibitors – including Lilly’s once-daily baricitinib – presented at American College of Rheumatology meeting are encouraging.
You may also be interested in...
Upadacitinib hit the primary endpoints in the first of six Phase III studies in rheumatoid arthritis, as well as several important secondary endpoints. Continued success in Phase III will position the candidate well in the race to market with Lilly.
Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.
Clinicians in the US can’t buy in to anti-TNF biosimilars yet, but wave of equivalence data featured at American College of Rheumatology meeting gives them a chance to evaluate products before they hit the market.